• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在肝癌细胞中抑制 Akt 信号转导可诱导凋亡细胞死亡,而与 Akt 激活状态无关。

Inhibition of Akt signaling in hepatoma cells induces apoptotic cell death independent of Akt activation status.

机构信息

Dipartimento di Morfologia ed Embriologia, Sezione di Anatomia Umana, Signal Transduction Unit, Universita' di Ferrara, via Fossato di Mortara 66, 44100, Ferrara, Italy.

出版信息

Invest New Drugs. 2011 Dec;29(6):1303-13. doi: 10.1007/s10637-010-9486-3. Epub 2010 Jul 14.

DOI:10.1007/s10637-010-9486-3
PMID:20628892
Abstract

The serine/threonine kinase Akt, a downstream effector of phosphatidylinositol 3-kinase (PI3K), is involved in cell survival and anti-apoptotic signaling. Akt has been shown to be constitutively expressed in a variety of human tumors including hepatocellular carcinoma (HCC). In this report we analyzed the status of Akt pathway in three HCC cell lines, and tested cytotoxic effects of Akt pathway inhibitors LY294002, Wortmannin and Inhibitor VIII. In Mahlavu human hepatoma cells Akt was constitutively activated, as demonstrated by its Ser473 phosphorylation, downstream hyperphosphorylation of BAD on Ser136, and by a specific cell-free kinase assay. In contrast, Huh7 and HepG2 did not show hyperactivation when tested by the same criteria. Akt enzyme hyperactivation in Mahlavu was associated with a loss of PTEN protein expression. Akt signaling was inhibited by the upstream kinase inhibitors, LY294002, Wortmannin, as well as by the specific Akt Inhibitor VIII in all three hepatoma cell lines. Cytotoxicity assays with Akt inhibitors in the same cell lines indicated that they were all sensitive, but with different IC50 values as assayed by RT-CES. We also demonstrated that the cytotoxic effect was through apoptotic cell death. Our findings provide evidence for its constitutive activation in one HCC cell line, and that HCC cell lines, independent of their Akt activation status respond to Akt inhibitors by apoptotic cell death. Thus, Akt inhibition may be considered as an attractive therapeutic intervention in liver cancer.

摘要

丝氨酸/苏氨酸激酶 Akt 是磷脂酰肌醇 3-激酶 (PI3K) 的下游效应物,参与细胞存活和抗细胞凋亡信号传导。已经表明 Akt 在包括肝细胞癌 (HCC) 在内的多种人类肿瘤中持续表达。在本报告中,我们分析了三种 HCC 细胞系中 Akt 途径的状态,并测试了 Akt 途径抑制剂 LY294002、Wortmannin 和 Inhibitor VIII 的细胞毒性作用。在 Mahlavu 人肝癌细胞中,Akt 通过其 Ser473 磷酸化、BAD 上 Ser136 的下游过度磷酸化以及特定的无细胞激酶测定被证明持续激活。相比之下,当用相同标准测试时,Huh7 和 HepG2 没有显示过度激活。Mahlavu 中 Akt 酶的过度激活与 PTEN 蛋白表达的丧失有关。在所有三种肝癌细胞系中,Akt 信号通过上游激酶抑制剂 LY294002、Wortmannin 以及特异性 Akt 抑制剂 VIII 被抑制。在相同细胞系中用 Akt 抑制剂进行的细胞毒性测定表明,它们都敏感,但 IC50 值不同,如 RT-CES 测定所示。我们还证明了这种细胞毒性作用是通过细胞凋亡死亡。我们的发现为其在一种 HCC 细胞系中的持续激活提供了证据,并且 HCC 细胞系独立于其 Akt 激活状态,通过细胞凋亡死亡对 Akt 抑制剂有反应。因此,Akt 抑制可能被认为是肝癌的一种有吸引力的治疗干预措施。

相似文献

1
Inhibition of Akt signaling in hepatoma cells induces apoptotic cell death independent of Akt activation status.在肝癌细胞中抑制 Akt 信号转导可诱导凋亡细胞死亡,而与 Akt 激活状态无关。
Invest New Drugs. 2011 Dec;29(6):1303-13. doi: 10.1007/s10637-010-9486-3. Epub 2010 Jul 14.
2
Sulfatase 2 protects hepatocellular carcinoma cells against apoptosis induced by the PI3K inhibitor LY294002 and ERK and JNK kinase inhibitors.硫酸酯酶 2 可保护肝癌细胞免受 PI3K 抑制剂 LY294002 和 ERK 和 JNK 激酶抑制剂诱导的细胞凋亡。
Liver Int. 2010 Nov;30(10):1522-8. doi: 10.1111/j.1478-3231.2010.02336.x. Epub 2010 Sep 8.
3
LY‑294002 enhances the chemosensitivity of liver cancer to oxaliplatin by blocking the PI3K/AKT/HIF‑1α pathway.LY‑294002 通过阻断 PI3K/AKT/HIF‑1α 通路增强肝癌对奥沙利铂的化疗敏感性。
Mol Med Rep. 2021 Jul;24(1). doi: 10.3892/mmr.2021.12147. Epub 2021 May 13.
4
Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma.“同类首创”双PI3K/BRD4抑制剂SF1126与索拉非尼在肝细胞癌中的单药活性及协同活性
Mol Cancer Ther. 2016 Nov;15(11):2553-2562. doi: 10.1158/1535-7163.MCT-15-0976. Epub 2016 Aug 5.
5
Targeting PI3K/Akt/HSP90 signaling sensitizes gastric cancer cells to deoxycholate-induced apoptosis.靶向 PI3K/Akt/HSP90 信号通路可增强胃癌细胞对脱氧胆酸盐诱导的凋亡作用。
Dig Dis Sci. 2011 Feb;56(2):323-9. doi: 10.1007/s10620-010-1294-2. Epub 2010 Jun 29.
6
Active form of AKT controls cell proliferation and response to apoptosis in hepatocellular carcinoma.AKT 的活性形式控制肝癌细胞的增殖和对细胞凋亡的反应。
Oncol Rep. 2014 Feb;31(2):573-80. doi: 10.3892/or.2013.2932. Epub 2013 Dec 16.
7
The Akt-inhibitor Erufosine induces apoptotic cell death in prostate cancer cells and increases the short term effects of ionizing radiation.Akt 抑制剂依鲁替尼诱导前列腺癌细胞凋亡,并增强电离辐射的短期作用。
Radiat Oncol. 2010 Nov 16;5:108. doi: 10.1186/1748-717X-5-108.
8
Inhibition of phosphatidylinositol 3-kinase-Akt signaling blocks growth, promotes apoptosis, and enhances sensitivity of small cell lung cancer cells to chemotherapy.抑制磷脂酰肌醇3-激酶-蛋白激酶B信号传导可阻断生长、促进凋亡,并增强小细胞肺癌细胞对化疗的敏感性。
Mol Cancer Ther. 2002 Sep;1(11):913-22.
9
Phosphatidylinositol 3-kinase/Akt positively regulates Fas (CD95)-mediated apoptosis in epidermal Cl41 cells.磷脂酰肌醇3激酶/蛋白激酶B正向调节表皮Cl41细胞中Fas(CD95)介导的细胞凋亡。
J Immunol. 2006 Jun 1;176(11):6785-93. doi: 10.4049/jimmunol.176.11.6785.
10
Docetaxel promotes cell apoptosis and decreases SOX2 expression in CD133‑expressing hepatocellular carcinoma stem cells by suppressing the PI3K/AKT signaling pathway.多西他赛通过抑制 PI3K/AKT 信号通路促进 CD133 表达的肝癌干细胞凋亡并降低 SOX2 表达。
Oncol Rep. 2019 Feb;41(2):1067-1074. doi: 10.3892/or.2018.6891. Epub 2018 Nov 27.

引用本文的文献

1
Exploring the effect and mechanism of fucoidan on liver cancer depending on network pharmacology and experimental verification.基于网络药理学和实验验证探索岩藻依聚糖对肝癌的作用及机制。
Front Chem. 2025 Jul 16;13:1638785. doi: 10.3389/fchem.2025.1638785. eCollection 2025.
2
HBx Drives Liver Cancer Stem Cell Generation Through Stimulating Glucose Metabolic Reprogramming.乙肝病毒X蛋白通过刺激葡萄糖代谢重编程驱动肝癌干细胞生成。
J Cell Mol Med. 2025 Jul;29(14):e70722. doi: 10.1111/jcmm.70722.
3
Comparative Genomic Analysis of Key Oncogenic Pathways in Hepatocellular Carcinoma Among Diverse Populations.

本文引用的文献

1
Targeting the phosphoinositide 3-kinase pathway in cancer.靶向癌症中的磷酸肌醇3-激酶通路。
Nat Rev Drug Discov. 2009 Aug;8(8):627-44. doi: 10.1038/nrd2926.
2
Targeting PI3K signalling in cancer: opportunities, challenges and limitations.靶向癌症中的PI3K信号通路:机遇、挑战与局限
Nat Rev Cancer. 2009 Aug;9(8):550-62. doi: 10.1038/nrc2664.
3
The phosphoinositide 3-kinase pathway in human cancer: genetic alterations and therapeutic implications.人类癌症中的磷酸肌醇 3-激酶途径:遗传改变与治疗意义。
不同人群肝细胞癌关键致癌途径的比较基因组分析
Cancers (Basel). 2025 Apr 13;17(8):1309. doi: 10.3390/cancers17081309.
4
Hepatocellular carcinoma: signaling pathways and therapeutic advances.肝细胞癌:信号通路与治疗进展
Signal Transduct Target Ther. 2025 Feb 7;10(1):35. doi: 10.1038/s41392-024-02075-w.
5
Extracellular vesicles in hepatocellular carcinoma: unraveling immunological mechanisms for enhanced diagnosis and overcoming drug resistance.肝细胞癌中的细胞外囊泡:揭示免疫机制以增强诊断和克服耐药性。
Front Immunol. 2024 Oct 28;15:1485628. doi: 10.3389/fimmu.2024.1485628. eCollection 2024.
6
Cuproptosis-related molecular classification and gene signature of hepatocellular carcinoma and experimental verification.肝细胞癌的铜死亡相关分子分类及基因特征与实验验证
Transl Cancer Res. 2024 Mar 31;13(3):1268-1289. doi: 10.21037/tcr-23-1876. Epub 2024 Mar 27.
7
All Three AKT Isoforms Can Upregulate Oxygen Metabolism and Lactate Production in Human Hepatocellular Carcinoma Cell Lines.三种 AKT 同工型均可上调人肝癌细胞系的氧代谢和乳酸生成。
Int J Mol Sci. 2024 Feb 11;25(4):2168. doi: 10.3390/ijms25042168.
8
Targeting EGFR/PI3K/AKT/mTOR Signaling in Hepatocellular Carcinoma.靶向肝细胞癌中的表皮生长因子受体/磷脂酰肌醇-3激酶/蛋白激酶B/雷帕霉素靶蛋白信号通路
Pharmaceutics. 2023 Aug 14;15(8):2130. doi: 10.3390/pharmaceutics15082130.
9
The Role of PI3K/AKT/mTOR Signaling in Hepatocellular Carcinoma Metabolism.PI3K/AKT/mTOR 信号通路在肝癌代谢中的作用。
Int J Mol Sci. 2023 Jan 31;24(3):2652. doi: 10.3390/ijms24032652.
10
Characterizing /PRL-3 as the Potential Prognostic Marker Gene for Liver Hepatocellular Carcinoma.将/PRL-3鉴定为肝细胞癌潜在的预后标志物基因
J Oncol. 2022 Sep 30;2022:2717056. doi: 10.1155/2022/2717056. eCollection 2022.
Curr Genomics. 2007 Aug;8(5):271-306. doi: 10.2174/138920207782446160.
4
Dysregulation of apoptosis in hepatocellular carcinoma cells.肝细胞癌细胞中细胞凋亡的失调。
World J Gastroenterol. 2009 Feb 7;15(5):513-20. doi: 10.3748/wjg.15.513.
5
Nuclear exclusion of p33ING1b tumor suppressor protein: explored in HCC cells using a new highly specific antibody.p33ING1b肿瘤抑制蛋白的核排除:使用一种新型高特异性抗体在肝癌细胞中进行研究。
Hybridoma (Larchmt). 2009 Feb;28(1):1-6. doi: 10.1089/hyb.2008.0058.
6
Nuclear translocation of active AKT is required for erythroid differentiation in erythropoietin treated K562 erythroleukemia cells.在促红细胞生成素处理的K562红白血病细胞中,活性AKT的核转位是红细胞分化所必需的。
Int J Biochem Cell Biol. 2009 Mar;41(3):570-7. doi: 10.1016/j.biocel.2008.07.002. Epub 2008 Jul 18.
7
Sorafenib in advanced hepatocellular carcinoma.索拉非尼用于晚期肝细胞癌
N Engl J Med. 2008 Jul 24;359(4):378-90. doi: 10.1056/NEJMoa0708857.
8
The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications.癌症中的PTEN/PI3K/AKT信号通路及其治疗意义
Curr Cancer Drug Targets. 2008 May;8(3):187-98. doi: 10.2174/156800908784293659.
9
Deregulation of the Akt pathway in human cancer.人类癌症中Akt信号通路的失调。
Curr Cancer Drug Targets. 2008 Feb;8(1):27-36. doi: 10.2174/156800908783497140.
10
The PI3K/Akt pathway: recent progress in the development of ATP-competitive and allosteric Akt kinase inhibitors.PI3K/Akt信号通路:ATP竞争性和变构Akt激酶抑制剂开发的最新进展
Curr Cancer Drug Targets. 2008 Feb;8(1):7-18. doi: 10.2174/156800908783497096.